Trial Profile
Phase IV, Non-comparative, Open Label, Multicenter, 28-Week Switching Study of Prasugrel Maintenance Dose From Clopidogrel in Patients With Acute Coronary Syndrome (ACS) Who Underwent a Percutaneous Coronary Intervention (PCI) in Taiwan
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 19 Feb 2024
Price :
$35
*
At a glance
- Drugs Prasugrel (Primary)
- Indications Acute coronary syndromes; Unstable angina pectoris
- Focus Adverse reactions; Therapeutic Use
- Sponsors Daiichi Sankyo Inc
- 02 Oct 2020 Status changed from active, no longer recruiting to completed.
- 02 Oct 2019 Status changed from recruiting to active, no longer recruiting.
- 12 Mar 2019 Planned End Date changed from 30 Jul 2020 to 30 Nov 2020.